IMmotion151: Patient-Reported Outcomes With First-line Atezolizumab + Bevacizumab vs Sunitinib in Treatment-Naive Metastatic RCC

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021